GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Debt-to-Revenue

TME Pharma NV (XPAR:ALTME) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

TME Pharma NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.17 Mil. TME Pharma NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. TME Pharma NV's annualized Revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.


TME Pharma NV Debt-to-Revenue Historical Data

The historical data trend for TME Pharma NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Debt-to-Revenue Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of TME Pharma NV's Debt-to-Revenue

For the Biotechnology subindustry, TME Pharma NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Debt-to-Revenue falls into.



TME Pharma NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

TME Pharma NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.166 + 0) / N/A
=N/A

TME Pharma NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


TME Pharma NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV (XPAR:ALTME) Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines